Announced Sat, 12 Sept, 2026 · 16:25 IST
Swiss unit clears US FDA inspection without observations
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.1%1-day move
₹167.50
prior close
₹174.99
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.4-0.6-1.6-1.9-3.1-3.3+2.0+2.0+1.8+1.1-9.0———
Up moveDown movePending
AI summary
Dishman Carbogen Amcis's wholly owned subsidiary CARBOGEN AMCIS AG has cleared its first US FDA inspection at its Vionnaz, Switzerland manufacturing site with no Form 483 observations. The successful inspection highlights strong quality standards and keeps the site's regulatory standing intact for serving global pharma customers.
Likely market impact
Positive for the subsidiary's credibility and ability to supply US markets without regulatory disruption.